Abou-Donia M and Lapadula DM. Mechanisms of organophosphorus ester-induced delayed neurotoxi-city: Type I and type II. Annu Rev Pharmacol Toxicol 1990;30:405-440.
Evoli A, Batocchi AP, and Tonali P. A practical guide to the recognition and management of myasthenia gravis. Drugs 1996;52:662-670.
Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galanthamine. Clin Ther 2001;23:A13-A24.
Felder C. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. FASEB J 1995;9:619-625.
Hoyng PF and van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;411-34.
Millard CB and Broomfield CA. Anticholinesterases: Medical applications of neurochemical principles. J Neurochem 1995 64:1909-1918.
Schneider LS. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med 2001;17:337-358.
Treatment of nerve gas poisoning. Med Lett 1995;37:43-44.
Was this article helpful?